Member Info for MisterPositive

Recoverable oil estimates for Chinese analogous 'Basins' with same geology & source rocks as Mongolia. * Junggar 10 bbo * Songliao 20 bbo * Bohai 40 bbo * Ordos 13 bbo * Tarim 14 bbo * Quaidam 2 bbo * Turpan 0.5 bbo * Santanghu 0.5 bbo That is 100 BBO (100 BILLION barrels) Recoverable.

The productive syn rift megasequence of China’s Songliao and Erlian basins is repeated across Mongolian basins. The productive pre-rift megasequence in China’s foreland basins of Junggar, Turpan and Tarim is present in western Mongolian basins although not as well developed. All these analogue basins are proven to be significant producers.

Hoof, You keep living in the last year, yet company has moved on under the new CEO after having to pick up the pieces of the previous moroniccc ceo and he is the one who did that stupid Bergen deal that led to the price drop and slow drift. Mike Buck reversed that ludicrous finance deal and stressed the BOD, we got to drill. Yes we all get frustrated. May be this is your way to vent your frustration. No body can change the past, but we can change the future, and change we Will. Just hang in there and try to look forward and NOT in your rear view mirror. Future is bright and is very near. I just read a note on the amazing geology of Mongolia and the rich source rocks that "actually catch fire" same as China who have developed a +100 Billion resource now, while Mongolia never explored. MATD could take the market by storm when this gets going. Almost there and that is hardest bit. ATB.

For Block XX are mega cheap. Discovery from the 2 Block XX appraisal type wells should be very profitable for MATD and provide very healthy cash flow for years to come. Hell MATD could self fund all future wells on both Block IV and V in my view. That is I believe the operating model that Mike Buck is pursuing.

Added more at 12.14 and 12.12....very tasty and cheap prices. Going to be a good summer. MATD very close to shifting gears here....can sense it. News should be with us soon.

I for one did not realise that IMM has got cancer & Diabetes drugs to enter Phase 2 soon. So IMM is not a one trick pony. Plus Lupuzor is still there with proven efficacy & no side effects. Defo 'Buy & Hold' for me.

Come on Mike, let's get this moving. RNS on Friday would be nice way indeed to enter June.

A1: The data issued this morning was the topline results of ImmuPharma’s Phase III study of Lupuzor for the treatment of lupus. What we reported was that we saw superior efficacy in the Lupuzor group of patients versus the placebo group of patients in quite a number of different measures, unfortunately, we didn’t meet the primary end point and that is to reach statistical significance. If I can just explain what that means, it means that if you have the advantage of a drug over placebo, the size of that advantage, between the response that you get in the active drug versus placebo group has to be a certain amount which when the statisticians work out the numbers, you get statistical significance. That’s a pretty widely used measure in our industry in terms of clinical studies. So, unfortunately, we didn’t see that statistical significance, so we didn’t meet the primary end point. However, the data that we did get from the study was extremely encouraging and in every measure that we look at, the active group with Lupuzor was superior to placebo so that is really big advantage. Just as importantly, we have a very very good safety profile and what I’ve always said when explaining Lupuzor to anybody, it’s all about the product profile. So, the product profile of any drug is how efficacious it is, how well it works on the patients and what the side effect profile is if there is one. So, despite the fact that we missed the primary end point, we do have a good drug here and it’s clear it works, we’ve got some good efficacious data and absolutely no side effects at all which we were expecting but to have it confirmed in a Phase III study is excellent. So, that overall is what we presented this morning.

Q2: How confident are you now then on the overall safety and efficacy of Lupuzor? A2: I’m extremely confident because you can’t deny, in the same way we can’t deny that we didn’t reach statistical end point, you can’t deny the fact that we got very good efficacy with the drug. On the safety profile, we’ve seen that before in previous studies and we weren’t expecting to see anything on the safety side but it’s always pleasing to get that confirmed in a larger study which we have with this Phase III. So, what you’ve got effectively, if we step aside from the result of this particular study, what you’ve got is confirmation with this Phase III that we have an efficacious drug with an absolute benign side effect profile.

Q3: So, what are the next steps regarding partnering solutions? A3: We put a little piece in the release today, just to say that we have had a lot of interest from larger pharmaceutical companies in the Lupuzor programme and all of those are potential partners were waiting for the data, like everybody else. So, we’ll be reaching out to them in the next few weeks and months and sharing the data with them and we’ll see where we get to with those discussions but there was very strong interest from a number of pharma partners.

Q5: Can you provide guidance on your current cash position? A5: Yes, we’re very strong actually on the cash position. We raised $10 million earlier this year, we already had cash in the bank and the previous guidance was that we had enough cash to the of 2018 before we raised that £10 million. Of course, what your listeners should understand is that now the Phase III study is completed, all the cost have that are now done so if one was to look at our expenditure over the last couple of years then you will see that expenditure come down quite dramatically going forward because we haven’t’ got the costs of the Phase III study. So, I can’t be exact on it in terms of cash flow and outlook, but we’ve certainly got at least 2 years, if not 3 years of money in the bank so we’re in a really strong position.

Q4: Will ImmuPharma now look at investing in your pipeline, outside of Lupuzor? A4: It’s an interesting question because clearly the focus on the company for the last 2-3 years, for obvious reasons, has been on Lupuzor and the Phase III study but we have tried to remind investors whenever we can that we do have other products in our portfolio. Primarily, we’ve got an oncology programme, a cancer product, which is ready to enter into Phase II with some very good pre-clinical Phase I data and we also have some pre-clinical work going on in the area of diabetes, in a specialist area of diabetes called NASH. So, yes, we will be looking at those now to see if we can bring those forward, but we shouldn’t forget Lupuzor and I do want to emphasise the fact that Lupuzor is still there and we’ll continue to push it forward primarily through discussions with pharma partners. As far as I’m concerned, we still have an extremely attractive drug, Lupuzor.

Tim McCarthy very upbeat...small piece from his Q&A interview below. Full interview is a must read. "I would remind your listeners once more, to step back from the disappointment of the result today in terms of the statistical significance, what it has confirmed today is we have an efficacious drug with a complete benign side effect profile. If I was a lupus patient searching around for treatment, I would say to my doctor ‘please, I would like to take Lupuzor because it’s clearly efficacious, it’s going to benefit me and I’m in no danger at all from any sort of side effect profile’. So, that’s a powerful profile and I think it will be an attractive proposition to a number of pharma companies."

Buccaneer, The 2 appraisal type wells in Block XX are to be drilled with a separate rig totally independent of Sinopec Rig being used for Blocks IV and V. As per last RNS, I think MATD are finalising the Block XX Rig tender process before Rig contract is granted. Block XX drills could run simultaneously in Eastern Mongolia while Sinopec drill rig works through Blocks IV and V in Western Mongolia. That would really spice things up.

Mike Buck the new CEO is quite a shrewd but conservative type of guy trying to best manage market expectations. He has built in 20 days extra contingency for Snow Leopard using 70 days as prudent guidance in my view. Last year guidance provided for Snow Leopard was 50 days. For the TD given, these onshore wells should come in early. Plenty of time to get them all done in my view.

Other 2 are appraisal type drills, both in Block XX in Eastern Mongolia, right next to PetroChina Blocks who currently produce 25,000 bopd. Planned 4 drills in 2018 by MATD are: 1. Snow Leopard (Block V) 2. Wild Horse (Block IV) 3. Gazelle (Block XX) 4. Name TBC (Block XX). Wells 3 and 4 are both appraisal type wells with 75% COS as they are adjacent to Block IX owned by the producing oil fields owned by PetroChina who originally had bought these from London based Soco International back in 2010.

buccaneer, KEY points to note: (1) As per 'footnote' at bottom of Page 18 - MATD Feb 2018 company presentation was based on Dec 2017 Economics & Oil prices. We know that Brent Crude price is already much higher now, so that NPV $1.27B would definitely be revised much Higher using today's oil prices. (2) Wild Horse target (Block IV) was upgraded from 290 MMBO to 490 MMBO after 3D interpretation. (3) FOX 200 MMBO target (Block V) was also highlighted by ongoing 3D interpretation, superseding the earlier Falcon 100 MMBO drill target. (4) Upside case was 750 MMBO recoverable, when Wild Horse was initially estimated at 290 MMBO. With upward revision at WH to 490 MMBO, surely the upside case now should be closer to +1 Billion barrels recoverable or higher.

Page 18......Success case Economics (Blocks IV / V)......MATD Feb 2018. http://www.petromatadgroup.com/wp-content/uploads/2018/01/1-Feb-2018-Investor-presentation-FINAL.pdf

Gradual and sustainable uplift is the key here as further updates come in. Spikes don't help having only a short term effect. If you believe in the science, then stick with it. No point selling when price is already on the low side.

Tony, I envy you. 7p is very good indeed. Mine was 15p at one stage but bought quite few to lower my weighted average to 12.30 now. Never been bothered with daily/weekly swings during the past quite months. Should have got it below 12p but that's in the past now. Pretty happy with proceedings here. Things about to get hot here indeed. ATB.